

Title (en)

1,4-BENZOTIAZEPINES TO TREAT OBESITY RELATED DISORDERS

Title (de)

1,4-BENZOTIAZEPINE ZUR BEHANDLUNG VON FETTSUCHTVERWANDTEN KRANKHEITEN

Title (fr)

1,4-BENZOTIAZEPINES DANS LE TRAITEMENT DES DESORDRES LIES A L'OBESITE

Publication

**EP 1218010 A2 20020703 (EN)**

Application

**EP 00945759 A 20000616**

Priority

- EP 0005541 W 20000616
- GB 9914745 A 19990624

Abstract (en)

[origin: WO0100185A2] The present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula (I) in which: n=0, 1 or 2; R1 and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo); R3 and R4 independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula =NR12 where R12 represents H, hydroxy, alkyl of 1 to 4 carbon atoms, a phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo; R5 represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula-COR13 in which R13 represents H, alkyl of 1 to 4 carbon atoms or phenyl, when R3 and R4 represent H or alkyl (optionally substituted with one or more halo), or (d) or a group of formula -S(O)pR14 in which p=1 or 2 and R14 is alkyl of 1 to 4 carbon atoms or phenyl, when R3 and R4 represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo; R6 and R7 are each H; R8 to R11 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.

[origin: WO0100185A2] The present invention provides a method of treating obesity and related conditions such as bulimia, anorexia, snacking, binge eating, non insulin dependent diabetes mellitus, hyperglycaemia, stress, hyperlipidaemia, and to aid to smoking cessation comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula (I) in which: n=0, 1 or 2; R1 and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo); R3 and R4 independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula =NR12 where R12 represents H, hydroxy, alkyl of 1 to 4 carbon atoms, a phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo; R5 represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula-COR13 in which R13 represents H, alkyl of 1 to 4 carbon atoms or phenyl, when R3 and R4 represent H or alkyl (optionally substituted with one or more halo), or (d) or a group of formula -S(O)pR14 in which p=1 or 2 and R14 is alkyl of 1 to 4 carbon atoms or phenyl, when R3 and R4 represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo; R6 and R7 are each H; R8 to R11 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.

IPC 1-7

**A61K 31/554; A61P 3/04; A61P 3/06; A61P 3/10; A61P 25/34; A61P 43/00**

IPC 8 full level

**A61K 31/554** (2006.01); **A61P 1/14** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01); **A61P 25/18** (2006.01);  
**A61P 25/34** (2006.01); **C07D 281/10** (2006.01)

CPC (source: EP)

**A61K 31/554** (2013.01); **A61P 1/14** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 25/18** (2017.12);  
**A61P 25/34** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 0100185A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 0100185 A2 20010104; WO 0100185 A3 20020411;** AU 5973600 A 20010131; CA 2376023 A1 20010104; EP 1218010 A2 20020703;  
GB 9914745 D0 19990825; JP 2003513008 A 20030408; MX PA01013420 A 20020722

DOCDB simple family (application)

**EP 0005541 W 20000616;** AU 5973600 A 20000616; CA 2376023 A 20000616; EP 00945759 A 20000616; GB 9914745 A 19990624;  
JP 2001505895 A 20000616; MX PA01013420 A 20000616